Clinical stage biotech company developing a new modality of oral biologics that act on cells in the small intestine. Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAXTM, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop a novel class of medicines with potential to transform the lives of patients with immune mediated diseases. We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function and fate coupled to a biomarker discovery effort with potential to bring precision to the treatment of immune-mediated diseases. Launched in 2018 by Third Rock Ventures with a $60 million Series A financing, Rheos is built on groundbreaking science from pioneers in the field, our passionate team of …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Argonaute RNA Ltd. is developing safe and reliable methods of temporarily silencing target genes in different tissue cells. Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. We show how our proprietary modification of small interfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. We use a novel method of stabilising the siRNA and thereby avoid a range of issues which have …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting iRhom2 for better treatment of autoimmune diseases SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases. drug …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

169 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering powdered, needle-free vaccines Orlance, Inc. is a Seattle-based biotech company developing the MACH-1TM platform of precise and localized powdered vaccines and immunotherapies for multiple indications including influenza, fungal diseases, and various cancers. The lead MACH-1 asset, a universal influenza vaccine, is targeted to enter Phase 1 trials in early 2027. MACH-1 needle-free vaccines and immunotherapies are powdered, low-dose, and shelf-stable nucleic acid formulations delivered pneumatically into the epidermis, the outermost active layer of skin. MACH-1’s epidermal targeting uniquely produces immediate and highly-localized dosing, generating both systemic antibody and T-cell and mucosal T-cell immunity.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Using circular RNA to control any gene, in any species, in any cell type. "Acquired by Ginkgo Bioworks in 2022" Control of any Gene in any Species or Cell Type Circularis has used the power of circular RNA to develop a novel method to study and regulate gene expression. This technology has enabled increased bio-therapeutic production, improved targeting of gene therapy, and optimized expression in poorly studied organisms. The elegant design and high throughput nature of this technology enables breakthrough solutions without prior knowledge of the regulatory elements or coding sequence. Gene Expression, Bioprocessing, Molecular Biology, Protein Expression, Drug Discovery, …

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dream ahead. RIBOPRO is an innovative service provider, producing high-quality, high-performance RNA products, which are used as powerful research tools and therapeutics. RiboPro offers both off-the-shelf and custom RNA products at competitive rates and turn-around times, effectively removing all barriers to successful use of RNA in the research and development of our customers. We have more than a decade of experience satisfying the RNA-related needs of almost 300 customers worldwide and thus we are confident that we can help you get your next project off to a good start. Let us worry about the quality and performance of your RNA, …

59 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

Advancing Glycan Mediated Therapy GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiNDTM platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein …

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Procavea Biotech is on a mission to solve the problem of delivering RNA-based drugs to non-liver tissues. At Procavea we're developing nonviral protein cages as carriers for the delivery of RNA Therapeutics to specific tissues in the body. Protein Engineering and RNA Delivery

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AOBiome is focused on transforming human health by developing microbiome-based therapies for inflammatory conditions. AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the microbiome for the development of diagnosis and therapeutic tools in cancer ! EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients. The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in …

123 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Orikine Bio is a pioneering biotech company dedicated to advancing the field of engineered cytokines with unparalleled biological features for the treatment of immune-mediated diseases. Our core mission is to unlock the untapped potential of cytokines, enabling us to offer transformative therapies that have the power to reshape the lives of patients around the globe.

59 similar entities Type: Startup Activities: deeptech biotech

Alternative to Animal Testing for Drug Development Cherry Biotech is a biomedical technology (Organ on Chip) company that develops instruments for drug discovery and personalised medicine. Its mission is to replace animal testing by reconstructing human tissue (Organoids) in vitro for drug testing. Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates. By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert …

141 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision Engineered Medicines to Silence Diseases Our 20-plus years of RNAi experience together with our validated mRNAi GOLDTM platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Next Frontier of Cell Therapy Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. Sonoma Bio has initiated two Phase 1 studies to evaluate the safety and proof-of-mechanism of the company’s lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis and hidradenitis suppurativa. …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovative therapies for autoimmune diseases. Global pioneer in cellular therapies based on TREGS cells. PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Driving immune-mediated therapeutic innovation for women. Freya Biosciences is a clinical-stage immunology company developing therapies treating inflammation and immune dysregulation in conditions that affect women. Freya is advancing a diversified pipeline, including two first-in-class Phase 2-ready assets for IVF-related embryo implantation failure and preterm birth. Freya’s science is powered by its DyscoverTM platform, a unique multi-omics data science platform built on a biobank of 1,000+ clinical samples derived from both observational and randomized, placebo controlled trials. This provides deep insights into disease pathway associated markers, allowing for de-risked target identification and patient stratification. Backed by a world-class team with a …

62 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Unlocking the Regulome for Drug Discovery Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision.

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing Cell Therapy with Protein Design Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLastTM), recruit a productive immune response in the tumor microenvironment (OutSmartTM), and achieve the potency (OutSpacersTM), specificity (Co-LOCKRTM), and safety (EGFRoptTM) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity. Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio. Biotechnology, Ultra Sensitive Immunoassays, and research

203 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines is a US-based clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies by chemically reprogramming stem cell fate and function to treat serious and currently incurable diseases. Leveraging cord blood stem cells from highly compatible 'super-donors' and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical …

311 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting Beta Cell recovery in Diabetes DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits. DiogenX is headquartered in Marseille, with labs in Nice (France). Biotechnology and Diabetes

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We want every patient to become a Cancer Survivor. Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cure with genes Healthy cells for healthy people Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, …

77 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells. LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing a maternal vaccine for Group B Streptococcus MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Better Biologics Through Chemistry Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crescendo Biologics - The T cell Enhancing Company Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical …

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Going beyond treatment, striving for cures Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering …

197 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics

Clinical-stage company developing proprietary protein superglue vaccines against infectious diseases, including CMV, EBV Spun out of the University of Oxford in 2017, SpyBiotech is a clinically validated vaccine company built on proprietary protein "superglue" technology. It snaps antigens onto a vaccine scaffold in a single step, giving us a faster, more reliable way to build robust vaccines. We apply this across two complementary platforms. Our virus-like particle (VLP) platform is Phase I-validated, and our viral vector platform extends the same plug-and-play approach to more targets. Together they form a flexible engine for vaccines against established and emerging diseases. Two lead …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineering Hope MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Novel Biotech dual-platform: therapeutic and drug-delivery MediSieve is a biotech developing a novel Magnetic Blood Filtration technology. Our nanoengineered magnetic particles enable the selective removal of specific substances - such as pathogens, antibodies, and inflammatory cytokines - from the bloodstream, much like dialysis, but with unmatched precision. Our platform's versatility allows for the selective removal of virtually any target, with our lead asset focused on neutralising antibody (NAb) removal to enhance AAV gene therapies for both initial dosing and redosing. Magnetic blood filtration and Blood-borne disease treatment

62 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

High-Capacity Gene Therapy Vector Platform to Address Prevalent Diseases Now part of Pacira Biosciences. GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium. biotechnology, gene …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Global Leader in Precision Targeting of PRAME Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/ Discovery of HLA-restricted tumor-associated peptides as cancer targets, Biomarkers, Immunomonitoring, Peptidomics & mass spectrometry, …

88 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

228 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinic-ready biotech developing human cell-derived secretome drugs to cure inflammation-related pathologies Med’Inn’Pharma (MIP) is a clinic-ready Biotech company that was founded in 2017 as a spin-off from the French blood bank establishment (EFS) and of the French National Institute of Health (INSERM). MIP is a pioneer in developing a new class disease modifying therapies dedicated to resolve pathologic inflammation in a wide range of degenerative diseases and conditions. Our founders are world leaders in immunology and inflammation-resolution, and have developed a patent protected process to harness bioactive molecules from physiologically conditioned human cells into a stable biologic drug product. …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nanomaterials as Nanomedicines: let's play collective! SUPERBRANCHE : Nanomedicine as a breakthrough to treat cancer We bring answers to the following issue: intratumoral injection of nanomaterials implying both accessibility and detection of the tumor beforehand. We position ourselves as a producer dedicated to the synthesis of architectured nanomaterials as simple as possible and of controlled size. Our modular technology platform presents both therapeutic and diagnosis applications. It consists in a magnetic nanoparticle coated by a tailor made branched architecture. Thanks to their optimized shape and stability, our compounds are well tolerated and can be administered intravenously, thus helping to the …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platform to transport and deliver nucleic acid to the central nervous system in a repetable and non-invasive way Harmonix, a breakthrough technology to deliver molecules, including viral and non-viral gene therapy, in a targeted and non-invasive manner, in the central nervous system. We develop innovative microbubbles who are able to encapsulate molecules and deliver them in a non invasive way in the brain. Biotech, Central Nervous System, Gene delivery, Non-viral and viral gene delivery, Research, and Glioblastoma

104 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Improving the safety and efficacy of gene therapies using AI Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration. Gene Control, RNA, Artificial Intelligence, Synthetic Biology, and …

70 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

Unlocking new therapeutic pathways for metabolic health Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy

221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

At Maze, we envision a world where genetic insights inspire new medicines. Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. The company’s pipeline is led by two wholly owned lead …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The CanVas platform is focused on developing novel cell therapies. The CanVas platform is spearheading the development of investigational allogeneic candidates for neurologic, rare and other serious diseases. Our world class team are dedicated to advancing a wave of investigational allogeneic products through excellence in translational research, clinical development and cell manufacturing. We are developing a pipeline of off-the-shelf cell therapies based on the pioneering Can-Vas platform. This could allow for the delivery of cell therapies to patients faster when they need it most and at greater scale. Our mission is to have a transformative impact on patients’ lives by …

245 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Beyond LNPs. Beyond the liver. A unique plant-based platform to unlock the potential of RNA therapies beyond vaccination Our mission is to unlock the full therapeutic potential of RNA medicines beyond the limitations of conventional lipid nanoparticles (LNPs) delivery and IVT RNA production systems, especially for in vivo cell-therapy developers. Serendip Innovations is developing a next-generation RNA platform that integrates both RNA manufacturing and targeted delivery beyond the liver. Using a unique plant-based production system and programmable phytovirus-like particles (phytoVLP), we generate functional RNAs directly encapsulated into a proprietary non-viral vector designed for targeted extrahepatic delivery, repeat dosing, and scalable …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerative diseases GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting anti-TSLP monoclonal antibody currently in a Phase 2 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific, which has broad therapeutic application across immunological diseases. The company is building a pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Windward Bio launched in January 2025 with a $200M Series A led by top-tier investors.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building new therapies atom by atom. Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanotherapeutics company pioneering new approaches to significantly improve patient outcomes for millions around the world by building new therapies atom by atom. The Nanobiotix philosophy is one rooted in designing pioneer physical-based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. The Nanobiotix global development strategy seeks to address the largest market in oncology—patients who receive radiotherapy as part of their treatment—with NBTXR3 (JNJ-1900). As the first product candidate from the company’s nanoradioenhancer platform, NBTXR3 aims to increase …

68 similar entities Type: SMB Activities: nanotech deeptech biotech Technologies: Synthetic Biology

Development of innovative drugs with curative potential in Immunology and Cancerology. Beta Innov SAS is an innovative pharmaceutical Research and Development company, created in March 2009 by patient families. Beta Innov aims to achieve a major therapeutic leap in the treatment of autoimmune diseases and Glioblastoma by using a physiological (Immunology) or metabolic (Glioblastoma) approach, avoiding the costs of gene therapies and the adverse effects of antibody therapies.

59 similar entities Type: Startup Activities: biotech manufacturing deeptech Technologies: Synthetic Biology

Overcoming Tumor Drug Resistance Founded in 2010, Advanced BioDesign is a clinical stage company developing a highly promising therapy for cancer with high unmet medical needs. Advanced Biodesign has developed a therapeutic approach based on a selective inhibition of ALDH enzymes. Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis. Oncology

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building the Future of Precision Medicines through V-Body, RNA and In Vivo Cell Engineering Platforms. At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement. Our approach integrates innovative target identification using advanced predictive models, antibody …

227 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Innovative personalized therapies targeting TREM-1 for life-threatening inflammatory syndromes such as septic shock Inotrem is a French biopharmaceutical company founded in 2013, with offices in Paris and a technology center in Nancy (France). Our mission is to improve public health by developing a new class of therapeutic solutions targeting the immunological pathway TREM-1 with a personalized medicine approach to manage life-threatening inflammatory syndromes with high unmet medical need. TREM-1 is a key amplifier of inflammatory responses implicated in various diseases such as septic shock, vaso-occlusive crisis in sickle cell disease, or hemorrhagic shock. Our lead drug candidate nangibotide has shown …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Since more than 10 years, AnyGenes® scientists develop and produce innovative high throughput screening products for signaling pathway analysis. These kits and reagents allow high throughput transcriptomic analysis of a large collection of signaling pathways in many species, biomarkers identification and validation, as well as validation of microarrays results. AnyGenes®, with its innovative & cost effective technologies, products and its proprietary molecular platform, helps scientists to accelerate their projects, publications, and biotech companies for drug development and biomarkers validation. Located in Paris, within Tenon Hospital in the 20th arrondissement, AnyGenes® constitutes a key player in the Biotechnology field. Supported by …

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The glyco design company Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved. Bioproduction and Cell …

84 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

385 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

283 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Changing the future of Oncology Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

59 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

264 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to Improving Life. Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com. Gene Editing and Gene Therapy

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Ultimate predictability Since 1999, genOway aims at bridging the gap between preclinical findings and clinical success with advanced, genetically engineered preclinical models and solutions. From customized mice and rats to ready-to-use cell lines, our solutions provide increased predictability and accelerate therapeutic breakthroughs. We work with 17 of the world’s Top pharma companies—as well as leading biotech firms, CROs, and academic institutions. At the heart of genOway is a team of 150+ skilled professionals, from 17 nationalities, all committed to advancing preclinical research. What We Offer • A catalogue of validated, ready-to-use mice and cell lines—developed in partnership with biopharma leaders …

148 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

60 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

A Path to SuperCellsTM Therapies GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCellsTM by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

159 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology Cancer continues to be a leading cause of disability and early mortality worldwide. Immune checkpoint blockade with PD/L-1 therapies such as Keytruda and Opdivo can induce complete and durable clinical responses in multiple tumors, a breakthrough in cancer treatment over the last decade. However, only around 20% of patients respond and many trials have failed Many R&D programs in multiple companies are attempting to improve the clinical efficacy of PD/L-1 therapies, but no solution is yet approved. Most of these approaches target T-cells or the tumour microenvironment. Patients with …

81 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

293 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A scalable in-vivo genetic medicine platform At Immitra Bio, we are pioneering a novel genetic medicine platform. Our innovative approach enables precise, durable, and safe gene modifications within blood stem cells, laying the foundation for scalable, curative in-vivo therapies.

122 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

270 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the broad potential of RNA medicines to transform human health We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, …

114 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Treating the untreatable BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable …

330 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reshaping rhBMP-2 Perspectives Relieving suffering and improving quality of life with next-generation orthobiologics. Regenerative Medicine, Biomaterials, Medical devices, Drug delivery, biotechnology, BMP2, Programmed Drug Release, and Instructive Tissue Scaffolds

230 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Consent-first clinico-genomic data that streamlines rare disease research. GeneHub is consent-first, real-world data from which Biopharma and CROs can recruit. GeneHub's mission is to make patient data move at the speed of science — with permission, with privacy, and with patients in total control. GeneHub is London-based and pre-seed backed by VCs and Innovate UK. Its initial focus is on rare diseases, where unmet needs are jaw-dropping.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating immunotherapies, transforming tomorrow. myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopesTM – which have the potential to unlock immunotherapy for large patient populations who currently do not respond. In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO …

58 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Data Analytics Synthetic Biology

Developing therapies for severe leukodystrophies Overview SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases. SynaptixBio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system. Pharmaceutical, Biotech, Leukodystrophy, Rare Disease, H-ABC, Hypomyelination, Basal Ganglia, Cerebrllum, Neurology, …

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Multi-target cell and gene therapies for unmet medical needs. Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapies, based on genetically modified safe lactic acid bacteria, address unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammatory diseases. After successfully completing Phase 1 and Phase 2 clinical studies in Diabetic Foot Ulcer (DFU) with our lead asset AUP-16, we're actively preparing a global DFU Phase 3 study. Other indications will follow In Oncology, we are building on impressive pre-clinical …

193 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mapping the universe of biology 🧬 NanoString Technologies, a Bruker Company, is a provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression …

87 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Using human genetics to transform cancer outcomes Pathios Therapeutics are world-leading experts with unique expertise in GPCR drug development, focused on GPR65 as a high-value immunology target with robust genetic links to multiple human diseases. Our clinical-stage oncology programme leverages cutting-edge proprietary genetic insights, transcriptomics, and functional immunology of GPR65 as a key immune cell sensor of acidosis in multiple pathological environments, to bring about a revolutionary new approach to treating a broad spectrum of cancers. We are also building an emerging pipeline in neuroinflammatory and neurodegenerative disorders leveraging the broader immunological roles of this receptor in cell types such …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming Rare Respiratory Disease Outcomes Using Inhaled Genes Therapy AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). The GTC was founded in 2001 to catalyse the application of pioneering research to gene therapy development and manufacturing related to cystic fibrosis and other respiratory diseases, and originated at Imperial College London and the Universities of Oxford and Edinburgh. AlveoGene has secured an exclusive licence to a proprietary and validated …

59 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Powering the future of gene editing development. Broken String Bioscience’s technology platform, INDUCE-seq®, supports the development of cell and gene therapies that are safer by design. INDUCE-seq®, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

The future of mRNA bioproduction. ByoRNA uses eucaryotic cells as natural biofactories to make high-quality messenger RNA (mRNAs). Our bioproduction technology will help mass produce mRNA and enhance productivity at a fraction of the current cost. By perfecting an overlooked mRNA production method, we are helping build a more sustainable planet, save cancer patients and give their grand-children a future.

55 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com Immuno-oncology and Re-programming the Tumor Microenvironment

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Chelator-free biologic radiopharma: metal binding engineered directly into antibody and nanobody scaffolds. Machine Bio is a pre-seed radiopharma platform company building chelator-free biologic-format radiopharmaceuticals. We engineer metal-binding architecture directly into antibody and nanobody scaffolds, so the protein itself carries the radiometal. The platform spans β-emitters (Lu-177, Tb-161) and α-emitters (Ac-225, Ra-223), opening therapeutic space synthetic chelator-conjugates can't reach. Our model is partnership-driven: partners bring targeting molecules, and we engineer chelator-free metal binding into them. Protein Synthesis, Protein Purification, Contract Protein Expression, R&D, Startup, Cell-Free Systems, and Supported Lipid Bilayer

64 similar entities Type: Startup Activities: deeptech biotech manufacturing Technologies: Synthetic Biology

Tackling metabolic disorders with non-coding RNAs Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals. See where Flublok® Influenza vaccine is available at www.flublok.com. We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology: 1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines 2. GeneXpress® …

133 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Human Resilience to Radiation. OUR MISSION: Protecting Lives Against Radiation Threats. USIL Therapeutics pioneers breakthrough medical solutions to safeguard people from the dangers of ionizing radiation. Our mission is to transform radiation defense with treatments and potential cures that go beyond symptomatic care, delivering true whole-body protection. Partnering with governments, defense, and energy sectors worldwide, we provide scalable, effective countermeasures that strengthen resilience and global preparedness in the face of nuclear and radiological risks. Radiation Protection and Drug Development

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exosome-based therapeutics Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‐CoV‐2 infection. Contact us at team@exogenus-t.com Biotechnology, Regenerative Medicine, Stem cells, exosomes, cell biology, and therapies

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

257 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology